Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-777-1760
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio Inc (NASDAQ:SPHS) released its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. View Sophiris Bio's Earnings History.
When is Sophiris Bio's next earnings date?
What price target have analysts set for SPHS?
3 equities research analysts have issued 1 year price objectives for Sophiris Bio's shares. Their predictions range from $3.50 to $6.00. On average, they anticipate Sophiris Bio's share price to reach $4.8333 in the next twelve months. This suggests a possible upside of 653.6% from the stock's current price. View Analyst Price Targets for Sophiris Bio.
What is the consensus analysts' recommendation for Sophiris Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.
Has Sophiris Bio been receiving favorable news coverage?
Media headlines about SPHS stock have trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sophiris Bio earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Sophiris Bio.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Selecta Biosciences (SELB), Cumberland Pharmaceuticals (CPIX), Tiziana Life Sciences (TLSA), Synlogic (SYBX), Aquestive Therapeutics (AQST), Eyenovia (EYEN), Neoleukin Therapeutics (NLTX), Alpine Immune Sciences (ALPN), Entasis Therapeutics (ETTX), Merrimack Pharmaceuticals (MACK), Inflarx (IFRX), Lipocine (LPCN), Marinus Pharmaceuticals (MRNS), Novan (NOVN) and NewLink Genetics (NLNK).
What other stocks do shareholders of Sophiris Bio own?
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
- Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
- Mr. Peter T. Slover, Chief Financial Officer (Age 44)
- Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
- Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board
Who are Sophiris Bio's major shareholders?
Which major investors are selling Sophiris Bio stock?
Which major investors are buying Sophiris Bio stock?
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $0.6414.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $19.38 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.
What is Sophiris Bio's official website?
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
